Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer.

Boyman O, Arenas-Ramirez N.

Swiss Med Wkly. 2019 Jan 23;149:w14697. doi: 10.4414/smw.2019.14697. eCollection 2019 Jan 14.

2.

Epigenetic mechanisms of tumor resistance to immunotherapy.

Arenas-Ramirez N, Sahin D, Boyman O.

Cell Mol Life Sci. 2018 Nov;75(22):4163-4176. doi: 10.1007/s00018-018-2908-7. Epub 2018 Aug 23. Review.

PMID:
30140960
3.

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.

Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, Sommer L, Boyman O.

Cell Rep. 2017 Jul 25;20(4):854-867. doi: 10.1016/j.celrep.2017.07.007.

4.

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.

Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G, Woytschak J, Regnier CH, Katopodis A, Boyman O.

Sci Transl Med. 2016 Nov 30;8(367):367ra166.

PMID:
27903862
5.

Endogenous polyclonal anti-IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation.

Spohn G, Arenas-Ramirez N, Bouchaud G, Boyman O.

J Allergy Clin Immunol. 2017 Jun;139(6):1957-1965.e3. doi: 10.1016/j.jaci.2016.09.033. Epub 2016 Nov 7.

PMID:
27833025
6.

IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation.

Fellmann F, Angelini F, Wassenberg J, Perreau M, Arenas Ramirez N, Simon G, Boyman O, Demaria O, Christen-Zaech S, Hohl D, Belfiore M, von Scheven-Gete A, Gilliet M, Bochud PY, Perrin Y, Beck Popovic M, Bart PA, Beckmann JS, Martinet D, Hofer M.

J Allergy Clin Immunol. 2016 Apr;137(4):1189-1196.e2. doi: 10.1016/j.jaci.2015.07.053. Epub 2015 Nov 20.

PMID:
26607704
7.

Interleukin-2: Biology, Design and Application.

Arenas-Ramirez N, Woytschak J, Boyman O.

Trends Immunol. 2015 Dec;36(12):763-777. doi: 10.1016/j.it.2015.10.003. Epub 2015 Nov 10. Review.

8.

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.

Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y, Bonalli M, McCabe MT, Creasy CL, Levesque MP, Boyman O, Santoro R, Shakhova O, Dummer R, Sommer L.

Nat Commun. 2015 Jan 22;6:6051. doi: 10.1038/ncomms7051.

PMID:
25609585
9.

Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer.

Rosalia RA, Arenas-Ramirez N, Bouchaud G, Raeber ME, Boyman O.

Curr Opin Chem Biol. 2014 Dec;23:39-46. doi: 10.1016/j.cbpa.2014.09.006. Epub 2014 Sep 29. Review.

10.

Membrane targeting of palmitoylated Wnt and Hedgehog revealed by chemical probes.

Gao X, Arenas-Ramirez N, Scales SJ, Hannoush RN.

FEBS Lett. 2011 Aug 4;585(15):2501-6. doi: 10.1016/j.febslet.2011.06.033. Epub 2011 Jul 2.

11.

Imaging the lipidome: omega-alkynyl fatty acids for detection and cellular visualization of lipid-modified proteins.

Hannoush RN, Arenas-Ramirez N.

ACS Chem Biol. 2009 Jul 17;4(7):581-7. doi: 10.1021/cb900085z.

PMID:
19505150

Supplemental Content

Loading ...
Support Center